Results 251 to 260 of about 122,145 (339)

Postprandial Glucagon Action in the Human Brain

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated fasting glucagon is linked to hyperglycemia, but postprandial glucagon effects are less understood. Recent evidence suggests metabolic benefits of rising glucagon after oral glucose intake, potentially impacting brain‐mediated whole‐body metabolism.
Robert Wagner, Stephanie Kullmann, Julia Hummel, Katsiaryna Prystupa, Elena Hosenfeld, Ralf Veit, Andreas L. Birkenfeld, Hans‐Ulrich Häring, Hubert Preissl, Andreas Fritsche, Andreas Peter, Martin Heni   +11 more
wiley   +1 more source

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To investigate adherence to and persistence with free combination therapy (daily basal insulin plus an injectable glucagon‐like peptide‐1 receptor agonist [GLP‐1 RA]) versus fixed‐ratio combination (FRC) therapy (basal insulin plus a GLP‐1 RA) among individuals with type 2 diabetes (T2D) in Japan.
Takeshi Miyatsuka, James Brash, Eleanor Davies, Elisabeth de Laguiche, Dorte Vistisen, Can Yin, Atif Adam   +6 more
wiley   +1 more source

Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed‐Dose Titration of Weekly Insulin Efsitora in Insulin‐Naïve Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the QWINT‐1 phase 3 Trial, once‐weekly insulin efsitora alfa (efsitora) administered using an innovative fixed‐dose regimen demonstrated noninferior HbA1c reduction versus once‐daily insulin glargine U100 (glargine) over 52 weeks in insulin‐naïve adults with type 2 diabetes.
Lisa Connery, Julio Rosenstock, Neda Rasouli, Alice Y. Y. Cheng, Andreas Liebl, Qianqian Wang, Vitoria Pires, Alastair Knights, Michael B. Davidson, Christopher J. Child   +9 more
wiley   +1 more source

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The fibrosis‐4 (FIB‐4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. Materials and Methods DECLARE‐TIMI 58 was a randomised, placebo‐controlled phase 3 trial investigating dapagliflozin ...
Jan Oscarsson, Monika Huhn, Yunyun Jiang, Ingrid Gause‐Nilsson, Stephen D. Wiviott, Filipe A. Moura, John P. H. Wilding, Simona Cernea, Luc Van Gaal, Avivit Cahn, Deepak L. Bhatt, Peter A. Johansson, C. David Sjöström   +12 more
wiley   +1 more source

Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. [PDF]

J Manag Care Spec Pharm
Marshall LZ, Gleason PP, Friedlander N, Farley J, Urick BY.   +4 more
europepmc   +1 more source

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney, Peter Rossing, Maria Eugenia Canziani, Maria Luiza Caramori, Ricardo Correa‐Rotter, Lisa Cronin, Christian Hugo, Bo Ji, Juliane Meyerhoff, Masaomi Nangaku, Arnold Silva, Dorothea Urbach, Shimoli V. Shah, Dick de Zeeuw, Katherine R. Tuttle   +14 more
wiley   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework. [PDF]

Cancer Med
Dalbeni A, Vicardi M, Natola LA, Cattazzo F, Auriemma A, Lombardi R, Cinque F, Dalle Carbonare L, Mantovani A, Sacerdoti D.   +9 more
europepmc   +1 more source